<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Transplants save lives and improve quality of life and saves the NHS money</title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written Evidence submitted by NHS Blood and Transplant</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (BTO0026)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Background</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. NHS Blood and Transplant</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">NHS Blood and Transplant (NHSBT) is a Special Health Authority that includes, amongst its statutory obligations, </span><span style="font-family:'Times New Roman'; font-size:11pt">an obligation </span><span style="font-family:'Times New Roman'; font-size:11pt">to ‘promote or secure the effective transplantation of organs and tissues for the purposes of the health service’. As such, NHSBT supports both living and deceased organ donation</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> although living organ donation is regulated by the Human Tissue Authority. NHSBT works in close collaboration with healthcare professionals</span><span style="font-family:'Times New Roman'; font-size:11pt"> and professional bodies</span><span style="font-family:'Times New Roman'; font-size:11pt">, devolved administrations and regulatory authorities, </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> is responsible for the identification and characterisa</span><span style="font-family:'Times New Roman'; font-size:11pt">tion of potential donors, obtaining</span><span style="font-family:'Times New Roman'; font-size:11pt"> consent</span><span style="font-family:'Times New Roman'; font-size:11pt"> (or </span><span style="font-family:'Times New Roman'; font-size:11pt">authorisation </span><span style="font-family:'Times New Roman'; font-size:11pt">in </span><span style="font-family:'Times New Roman'; font-size:11pt">Scotland</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">from the family </span><span style="font-family:'Times New Roman'; font-size:11pt">for organ and tissue donation </span><span style="font-family:'Times New Roman'; font-size:11pt">and offering those </span><span style="font-family:'Times New Roman'; font-size:11pt">donated </span><span style="font-family:'Times New Roman'; font-size:11pt">organs to surgeons for patients on the national transplant list. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.1 </span><span style="font-family:'Times New Roman'; font-size:11pt">Many organisations are involved in the</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">delivery of organ donation and transplantation in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> but NHSBT plays a central role in working with clinicians, professional bodies, commissioners, regulators and national health departments as well as lay members, patients and patient groups, to improve the service to </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients.  </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The policies for patient selection and organ allocation are developed by the Solid Organ Advisory Groups, which include representation from health care professionals involved in transplantation, after consultation with patients, patient groups and charities and other interested parties. These policies are reviewed and, after agreement, implemented by the Transplant Review Committee, a sub-group of the NHSBT Board. Clinical Governance and Outcome monitoring is led by NHSBT, working n close collaboration with clinicians, commissioners, regulators and national health departments.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">As a consequence of implementation of the recommendations of the Organ Donor Task Force, the number of deceased donors has increased year on year: th</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">re were 936 deceased donors in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">between 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> April 2013 and 15</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> December 2013</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">(compared with 817 in the same period last in 2012)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> resulting in 2</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt">483 solid organ transplants. </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he number of people waiting for a solid organ transplant as of 15</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> December is 7</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt">083</span><span style="font-family:'Times New Roman'; font-size:11pt"> (data from NHSBT www.odt.nhs.uk)</span><span style="font-family:'Times New Roman'; font-size:11pt">. The availability of organs is insufficient to meet the demands.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Transplants save lives and improve quality of life and save the NHS money</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Solid organ transplants are not only life saving and life enhancing but save the NHS money as dialysis is more expensive than transplantation. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">The consequence of organ shortage</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Kidney transplantation is offered mainly for those on dialysis and for</span><span style="font-family:'Times New Roman'; font-size:11pt"> the 5</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt">767</span><span style="font-family:'Times New Roman'; font-size:11pt"> people awaiting a deceased donor kidney transplant</span><span style="font-family:'Times New Roman'; font-size:11pt">.  T</span><span style="font-family:'Times New Roman'; font-size:11pt">he average wait</span><span style="font-family:'Times New Roman'; font-size:11pt">ing time</span><span style="font-family:'Times New Roman'; font-size:11pt"> is just over 3 years. For other organs, such as liver, heart or lung, the</span><span style="font-family:'Times New Roman'; font-size:11pt"> transplants are done to save life. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Selection criteria are developed, in part, to restrict access to the transplant list to ensure that those who are listed have a realistic expectation of being offered a gr</span><span style="font-family:'Times New Roman'; font-size:11pt">aft, yet</span><span style="font-family:'Times New Roman'; font-size:11pt"> even with such restricted access to the transplant list, up to </span><span style="font-family:'Times New Roman'; font-size:11pt">20% of the 503 people currently</span><span style="font-family:'Times New Roman'; font-size:11pt"> listed for a </span><span style="font-family:'Times New Roman'; font-size:11pt">liver </span><span style="font-family:'Times New Roman'; font-size:11pt">graft </span><span style="font-family:'Times New Roman'; font-size:11pt">and 490 people currently listed for a heart or lung transplant (as of 15</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> December 2013) </span><span style="font-family:'Times New Roman'; font-size:11pt">become too sick or die before a suitable graft is available. If more grafts were available, more people would be listed</span><span style="font-family:'Times New Roman'; font-size:11pt">, fewer would die awaiting a graft</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">more </span><span style="font-family:'Times New Roman'; font-size:11pt">lives</span><span style="font-family:'Times New Roman'; font-size:11pt"> would be</span><span style="font-family:'Times New Roman'; font-size:11pt"> saved and improved.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">4</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Organs are</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> biomaterials</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">therefore </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">carry risk</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> which can be mitigated but not abolished</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Organs are from humans and carry risk: these risks include the inadvertent transmission of some infections and cancer as well as other conditions such as metabolic </span><span style="font-family:'Times New Roman'; font-size:11pt">and autoimmune </span><span style="font-family:'Times New Roman'; font-size:11pt">diseases. </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT has issued guidance to ensure that potential transplant recipients are given appropriate information on the risks associated with transplantation (as well as the benefits) and so</span><span style="font-family:'Times New Roman'; font-size:11pt"> they can</span><span style="font-family:'Times New Roman'; font-size:11pt"> give fully informed consent.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">5</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. Use of donated organs requires a risk assessment</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The risks associated with organ transplantation </span><span style="font-family:'Times New Roman'; font-size:11pt">(including inadvertent transmission of disease) </span><span style="font-family:'Times New Roman'; font-size:11pt">must be balanced against the risks of death without a transplant. The </span><span style="font-family:'Times New Roman'; font-size:11pt">risks can and are mitigated but cannot be abolished. In the limited time between death being declared or treatment considered futile and agreement made for treatment to be withdrawn, families must be asked for and give consent</span><span style="font-family:'Times New Roman'; font-size:11pt"> (or </span><span style="font-family:'Times New Roman'; font-size:11pt">authorisation </span><span style="font-family:'Times New Roman'; font-size:11pt">in Scotland) </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">then </span><span style="font-family:'Times New Roman'; font-size:11pt">an assessment made </span><span style="font-family:'Times New Roman'; font-size:11pt">to assess</span><span style="font-family:'Times New Roman'; font-size:11pt"> associated risk. This </span><span style="font-family:'Times New Roman'; font-size:11pt">assessment </span><span style="font-family:'Times New Roman'; font-size:11pt">includes </span><span style="font-family:'Times New Roman'; font-size:11pt">review</span><span style="font-family:'Times New Roman'; font-size:11pt"> of </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">medical and social history (</span><span style="font-family:'Times New Roman'; font-size:11pt">obtained </span><span style="font-family:'Times New Roman'; font-size:11pt">from the hospital records, family and family doctor), review of previous available investigations and agreed screening tests for viruses and other infections, cancer and the state of the organs. Information is made available to the </span><span style="font-family:'Times New Roman'; font-size:11pt">recipient </span><span style="font-family:'Times New Roman'; font-size:11pt">surgeon according to agreed protocols and the surgeon must decide whether to accept the organ for a given patient (who </span><span style="font-family:'Times New Roman'; font-size:11pt">will have given informed consent</span><span style="font-family:'Times New Roman'; font-size:11pt">). </span><span style="font-family:'Times New Roman'; font-size:11pt">Furthermore, the degree of risk taken will depend not only on the donor and organ characteristics but also the recipient: for example, a liver from a donor with a risk of cancer transmission may be accepted for a person in acute liver failure and so expected to die within three days if no graft were available but declined for a recipient with end-stage cirrhosis who has a life expectation without transplantation, of 8 months.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">6</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">There are national and international protocols for donor characterisation</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Donor characterisation is the process by which information is sought and made available for risk assessment. The information includes a medical, social and travel history taken from the clinical staff, the hospital records, the family and, where possible, the family doctor. The available investigations are reviewed and additional tests requested. </span><span style="font-family:'Times New Roman'; font-size:11pt">The tests required for donor characterisation have been described by a variety of int</span><span style="font-family:'Times New Roman'; font-size:11pt">ernational and national bodies, </span><span style="font-family:'Times New Roman'; font-size:11pt">including </span><span style="font-family:'Times New Roman'; font-size:11pt">the Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">), the Council of Europe </span><span style="font-family:'Times New Roman'; font-size:11pt">and professional organisations. </span><span style="font-family:'Times New Roman'; font-size:11pt">The characterisation of donors is regulated by the Human Tissue Authority under the European Union Directive on Organ Donation.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The microbiological investigations requested by NHSBT </span><span style="font-family:'Times New Roman'; font-size:11pt">are</span><span style="font-family:'Times New Roman'; font-size:11pt"> wider than required </span><span style="font-family:'Times New Roman'; font-size:11pt">under the EU Directive but </span><span style="font-family:'Times New Roman'; font-size:11pt"> include routinely Hepatitis B and C viruses, Cytomegalovirus, Human Immunodeficiency Virus, Human T-lymphocytic virus, syphilis,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> Epstein-Barr virus. </span><span style="font-family:'Times New Roman'; font-size:11pt">Tests for o</span><span style="font-family:'Times New Roman'; font-size:11pt">ther infectious agents, such as malaria, Trypanosomiasis cruzi or </span><span style="font-family:'Times New Roman'; font-size:11pt">West Nile</span><span style="font-family:'Times New Roman'; font-size:11pt"> virus will be requested as </span><span style="font-family:'Times New Roman'; font-size:11pt">clinically indicated</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">e.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> on the basis of travel history.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">6.2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">These guidelines and regulations</span><span style="font-family:'Times New Roman'; font-size:11pt"> all recognise that </span><span style="font-family:'Times New Roman'; font-size:11pt">the decision to use organs involves balancing risks. They also recognise that </span><span style="font-family:'Times New Roman'; font-size:11pt">not all possible information will be available, because of the limitations of available investigations and the time required for some blood tests and, furthermore, that some blood tests may fail to detect infection or may wrongly diagnose infection.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">7. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Absolute contra-indications for organ donation</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT, in collaboration</span><span style="font-family:'Times New Roman'; font-size:11pt"> with professional organisations and clinicians, have agreed a short list of absolute contra-indications to organ donation (</span><a href="http://odt.nhs.uk/pdf/contraindications_to_organ_donation.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://odt.nhs.uk/pdf/contraindications_to_organ_donation.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. These</span><span style="font-family:'Times New Roman'; font-size:11pt"> include a d</span><span style="font-family:'Times New Roman'; font-size:11pt">efinite, probable or possible case of human TSE, including CJD and vCJD, individuals whose blood relatives have had familial CJD, other neurodegenerative diseases associated with infectious agents, TB: active and untreated and HIV</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease (but not HIV infection</span><span style="font-family:'Times New Roman'; font-size:11pt">).</span><span style="font-family:'Times New Roman'; font-size:11pt"> Other contra-indications include widespread cancers and untreated sepsis.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">8</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Risks of prion transmission by organ transplantation</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It is</span><span style="font-family:'Times New Roman'; font-size:11pt"> recognised that </span><span style="font-family:'Times New Roman'; font-size:11pt">sporadic </span><span style="font-family:'Times New Roman'; font-size:11pt">CJD has been transmitted by transplantation of corneal tissue and dura mater in a very small number of cases. We are not aware of any case of prion transmission by solid organ transplantation in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> or elsewhere. </span><span style="font-family:'Times New Roman'; font-size:11pt">We are, however, not complacent. </span><span style="font-family:'Times New Roman'; font-size:11pt">We recognise the potential possibility that prion transmission may occur as a consequence of organ transmission and, as with any surgical procedure, surgical instruments us</span><span style="font-family:'Times New Roman'; font-size:11pt">ed in retrieval or implantation</span><span style="font-family:'Times New Roman'; font-size:11pt"> may transmit disease to other patients. We also recognise the potential for immunosuppressive agents, required to prevent graft loss, could have an impact on </span><span style="font-family:'Times New Roman'; font-size:11pt">prion disease </span><span style="font-family:'Times New Roman'; font-size:11pt">progression, although whether that impact is positive or negative is unknown. </span><span style="font-family:'Times New Roman'; font-size:11pt">We also appreciate that any lack of appearance of the effect of prion infection may not yet be apparent in the transplan</span><span style="font-family:'Times New Roman'; font-size:11pt">t population because of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> incubation times.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">9. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Mitigation of risk of prion transmission by organ donation and transplantation</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A number of steps are in place to mitigate the risks of prion transmissi</span><span style="font-family:'Times New Roman'; font-size:11pt">on. Specialist Nurses in Organ D</span><span style="font-family:'Times New Roman'; font-size:11pt">onation are </span><span style="font-family:'Times New Roman'; font-size:11pt">highly </span><span style="font-family:'Times New Roman'; font-size:11pt">trained by NHSBT and follow well documented protocols, specifically seeking information about risks of, amongst other issues, exposure to possi</span><span style="font-family:'Times New Roman'; font-size:11pt">ble prion-contaminated material and</span><span style="font-family:'Times New Roman'; font-size:11pt"> a personal or family history of unexplained degenerative neurological disease.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This level of inquiry is much deeper</span><span style="font-family:'Times New Roman'; font-size:11pt"> and wider</span><span style="font-family:'Times New Roman'; font-size:11pt"> than for living patients undergoing routine </span><span style="font-family:'Times New Roman'; font-size:11pt">or emergency </span><span style="font-family:'Times New Roman'; font-size:11pt">surgery.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">It should be noted that p</span><span style="font-family:'Times New Roman'; font-size:11pt">eople dying from any cause of degenerative </span><span style="font-family:'Times New Roman'; font-size:11pt">neurological </span><span style="font-family:'Times New Roman'; font-size:11pt">disease are unlikely to become organ donors because their mode of death </span><span style="font-family:'Times New Roman'; font-size:11pt">usually </span><span style="font-family:'Times New Roman'; font-size:11pt">renders them unlikely to be candidates for organ donation.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9.2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Should a solid organ recipient develop a known donor transmitted disease, clinicians are obliged under </span><span style="font-family:'Times New Roman'; font-size:11pt">the terms of </span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt">heir licence, to report this to NHSBT who will investigate whether any other people received an organ from that donor and ensure that there is a full investigation and appropriate reporting.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">0</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. Risks of cancer transmission</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Organ donation is also associated with the risk of inadvertent transmission of cancer and there are national and international guidelines to support the surgeon in making a decision. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1</span><span style="font-family:'Times New Roman'; font-size:11pt">0.1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In some cases, the presence or past history of cancer is known at the time of donation or a cancer is detected at the time of retrieval or preparation</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the organ for implantation.</span><br /><span style="font-family:'Times New Roman'; font-size:11pt">A decision whether or not to use organs from such donors will depend on many factors including the type of cancer, the stage of cancer, the treatment given and the interval between treatment and death. In many cases, the presence of cancer in the transplanted organs is unknown at the time of donation and transplantation. Indeed, a recent review of the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> experience showed that in all cases (fewer than 0.05% transplants) of transmitted cancer, the presence of tumour was not known at the time of donation.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. Transmission of other conditions</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Both metabolic and autoimmune conditions can be transmitted by organ transplantation.  These occur rarely: in the last 12 months, NHSBT has been informed of one case of transmitted autoimmune thrombocytopenic purpura and one case of acute intermittent porphyria.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Balance of risks</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT takes its responsibilities very seriously but for organ transplantation, the balance of risks for the patient is quite different to that of blood and tissues. The number of deaths and removals (because of failing health) from the national waiting list and the poor quality of life of those awaiting a transplant mean that any reduction in the donor pool will have an adverse impact on the patients and their family: the removal of just one donor will mean</span><span style="font-family:'Times New Roman'; font-size:11pt">, o</span><span style="font-family:'Times New Roman'; font-size:11pt">n average, that 3 or 4 people will be denied a transplant and maybe one will die. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">3</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">The Organ Donation Strategy (Ta</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">king T</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">ransplantation to 2020)</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The initial strategy for NHSBT was set by the Organ Donation Task Force; this group made a number of recommendations to improve organ donation in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt">. The Task Force claimed that, if all the recommendations were implemented, then a 50% increase in the number of deceased organ donors should be achieved in 5 years. This target was reached on time in April 2013. To follow, the initial strategy, a</span><span style="font-family:'Times New Roman'; font-size:11pt"> new organ donation strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> – Taking Organ Transplantation to 2020 -</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">was developed after widespread consultation with lay, patient and professional groups and advice from international organisations. This new strategy </span><span style="font-family:'Times New Roman'; font-size:11pt">was si</span><span style="font-family:'Times New Roman'; font-size:11pt">gned off by ministers from all four</span><span style="font-family:'Times New Roman'; font-size:11pt"> national health departments and was launched in 2013. It is a strategy for the whole </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> and not just for NHSBT. The new strategy focuses on increasing the number of solid organ transplants and </span><span style="font-family:'Times New Roman'; font-size:11pt">improving </span><span style="font-family:'Times New Roman'; font-size:11pt">the outcome for the patients. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">14</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Transplantation </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">rates </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">can be increased without reduction in quality</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> has the second highest family refusal rate for consent/authorisation for organ donation in </span><span style="font-family:'Times New Roman'; font-size:11pt">Europe</span><span style="font-family:'Times New Roman'; font-size:11pt"> (at 46%)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> so the greatest gain in the number of transplants will come from reducing this refusal rate. </span><span style="font-family:'Times New Roman'; font-size:11pt">Some o</span><span style="font-family:'Times New Roman'; font-size:11pt">ther European countries </span><span style="font-family:'Times New Roman'; font-size:11pt">(such as </span><span style="font-family:'Times New Roman'; font-size:11pt">Spain</span><span style="font-family:'Times New Roman'; font-size:11pt">) </span><span style="font-family:'Times New Roman'; font-size:11pt">have refusal rates of 10% or less. </span><span style="font-family:'Times New Roman'; font-size:11pt">Furthermore, over the last 6 years, the UK has had an increase </span><span style="font-family:'Times New Roman'; font-size:11pt">of</span><span style="font-family:'Times New Roman'; font-size:11pt"> nearly 60% in the number of deceased donors, and this is associated with an improving survival following transplantation showing that the increase in organ donation is not at the expense of worse outcomes for patients</span><span style="font-family:'Times New Roman'; font-size:11pt"> showing that increased activity need not come at the expense of reducing quality</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">14.1</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">new organ donation s</span><span style="font-family:'Times New Roman'; font-size:11pt">trategy does include </span><span style="font-family:'Times New Roman'; font-size:11pt">an aim to</span><span style="font-family:'Times New Roman'; font-size:11pt"> increase</span><span style="font-family:'Times New Roman'; font-size:11pt"> the</span><span style="font-family:'Times New Roman'; font-size:11pt"> use of higher risk organs. This aim refers to those organs that might be less likely to function and calls for research to improve the quality of organs (such as normothermic pulsatile </span><span style="font-family:'Times New Roman'; font-size:11pt">organ </span><span style="font-family:'Times New Roman'; font-size:11pt">perfusion</span><span style="font-family:'Times New Roman'; font-size:11pt"> or normothermic regional perfusion</span><span style="font-family:'Times New Roman'; font-size:11pt">): the strategy nowhere encourages the greater use of organs from potential donors with the risk of transmitting infection or other disease or lowering the standard assessment of donors.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">14.2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">It must be stressed that implementation of this Strategy does in no way imply any lowering of standards; indeed, the Strategy r</span><span style="font-family:'Times New Roman'; font-size:11pt">equires NHSBT and others to work to </span><span style="font-family:'Times New Roman'; font-size:11pt">raise the quality of donated organs.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">15</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The potential for solid organ transplants to transmit diseases is accepted and many </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">processes are in place to mitigate this risk. </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT and the donation and transplant communities are not complacent about </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">these</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">risks</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3 </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">I</span><span style="font-family:'Times New Roman'; font-size:11pt">t must be recognised that the use of organs for transplantation involves balancing </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">risks: the risk of inadvertent disease transmission is currently very low (less than 1%) </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">while the death rate without transplantation approaches 20% for some organs. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4. </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT works closely with both national and international organisations to ensure </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">standards in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> are at least as good as those in other countries.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">5</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The new</span><span style="font-family:'Times New Roman'; font-size:11pt"> organ donation</span><span style="font-family:'Times New Roman'; font-size:11pt"> strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">builds on the success of the last 5 years and aims to increase the number and quality of transplants but this </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">does not mean an increase in risk of disease transmission.</span></p><p style="font-size:11pt; line-height:150%; margin:6pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>